ロード中...
Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
This open‐label, multicenter, phase I therapeutic protein‐drug interaction study was designed to evaluate the potential effect of guselkumab, a fully human anti‐interleukin‐23 immunoglobulin G1 lambda monoclonal antibody, on the pharmacokinetics of a cocktail of representative cytochrome P450 (CYP)...
保存先:
| 出版年: | Clin Transl Sci |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7719363/ https://ncbi.nlm.nih.gov/pubmed/32407591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12807 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|